SMAD3 and asthma: In addition to IL4R and SMAD3, these prioritized genes are known targets of existing asthma drugs including IL6 (clazakizumab, sirukumab), TNFSF4 (oxelumab), TSLP (tezepelumab), CCR4 (mogamulizumab), IL13 (anrukinzumab, lebrikizumab, dectrekumab, and tralokinumab), IL5 (mepolizumab, reslizumab), and IL2RA (daclizumab).